Ocul Surf:三种干眼问卷调查的Rasch分析

2017-03-27 luowenbo MedSci原创

该研究用Rasch分析评估三种干眼问卷调查---眼部舒适度指数(中文版)的心理测量学特性(OCI)、眼表疾病(OSDI)和McMonnies问卷,同时,还评估该问卷得分与客观干眼病(OED)临床检测试验的相关性。

三种干眼问卷调查的Rasch分析

该研究用Rasch分析评估三种干眼问卷调查---眼部舒适度指数(中文版)的心理测量学特性(OCI)、眼表疾病(OSDI)和McMonnies问卷,同时,还评估该问卷得分与客观干眼病(OED)临床检测试验的相关性。

研究中,238名OED患者填写了中文版OCI、OSDI和McMonnies问卷。OED客观临床检测试验包括视力(VA)、荧光素泪膜破裂时间(TBUT)、角膜荧光素染色、Schirmer I检测和睑板腺分级。Rasch分析是用于评估问卷的心理测量学和Spearman秩相关。

OCI问卷中,人分离为2.31,项目infit与outfit统计范围分别为0.74-1.14与0.75-1.32(针对1.54分对数)。OSDI问卷中,人分离为0.94,它的三种问卷分量表都没有提供基于Rasch分析的有效测量方法。McMonnies问卷中,人分离为1.17,项目infit与outfit统计范围分别为0.7-1.21与0.51-3.49.问卷得分与干眼症临床检测试验之间存在弱相关。OSDI评分与VA、荧光素TBUT、Schirmer I试验和角膜荧光素染色试验存在弱相关。McMonnies评分与VA、荧光素TBUT、Schirmer I试验、角膜荧光素染色和睑板腺分级存在弱相关。

OCI问卷是唯一一份基于Rasch分析提供有效测量方法的问卷,虽然仍然存在轻微的缺陷。OCI评分与荧光素TBUT、Schirmer I试验和角膜荧光素染色存在弱相关。由于干眼病症状与体征的脱节与检测试验重复性矛盾的存在,使用主管或客观指标管理临床干眼病患者与指示临床试验终点时,应当非常谨慎。

原文出处:


本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055316, encodeId=b97220553160a, content=<a href='/topic/show?id=72c69e2076e' target=_blank style='color:#2F92EE;'>#问卷调查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97207, encryptionId=72c69e2076e, topicName=问卷调查)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Oct 02 18:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938662, encodeId=ec2019386626a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 04 08:00:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527312, encodeId=cdcd152e3123b, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Tue Mar 28 15:00:00 CST 2017, time=2017-03-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055316, encodeId=b97220553160a, content=<a href='/topic/show?id=72c69e2076e' target=_blank style='color:#2F92EE;'>#问卷调查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97207, encryptionId=72c69e2076e, topicName=问卷调查)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Oct 02 18:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938662, encodeId=ec2019386626a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 04 08:00:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527312, encodeId=cdcd152e3123b, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Tue Mar 28 15:00:00 CST 2017, time=2017-03-28, status=1, ipAttribution=)]
    2017-06-04 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055316, encodeId=b97220553160a, content=<a href='/topic/show?id=72c69e2076e' target=_blank style='color:#2F92EE;'>#问卷调查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97207, encryptionId=72c69e2076e, topicName=问卷调查)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Oct 02 18:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938662, encodeId=ec2019386626a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jun 04 08:00:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527312, encodeId=cdcd152e3123b, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Tue Mar 28 15:00:00 CST 2017, time=2017-03-28, status=1, ipAttribution=)]

相关资讯

欧洲干眼病处方药Ikervis(环孢素)上市

日本眼科领域领导者参天制药(Santen Pharma)近日宣布,该公司研发的眼科药物Ikervis(ciclosporin,环孢素)获欧盟委员会(EC)批准,用于经人工泪液治疗未得到改善的干眼病成人患者严重角膜炎的治疗。 干眼症(dry eye)又名角结膜干燥症(KCS),是指任何原因造成的泪液质或量异常或动力学异常,导致泪膜稳定性下降,并伴有眼部不适和(或)眼表组织病变特征的多种疾病

Shire在美国推出干眼病新药Xiidra,艾尔健丽眼达(Restasis)霸主地位不保

英国制药公司Shire近日宣布,在美国市场推出眼科药物Xiidra(lifitegrast滴眼液),该药于今年7月11日获得美国食品和药物管理局(FDA)批准,用于干眼病(DED)症状和体征的治疗,这是FDA批准的首个治疗干眼病的淋巴细胞功能相关抗原 1(LFA-1) 拮抗剂类新药,同时也是美国市场中唯一一种处方滴眼液,每日使用2次,每次相隔大约12小时。 Xiidra是过去13年里干眼病治疗领

太阳药业公布干眼病治疗方案Seciera™第三阶段临床试验良好结果

印度太阳药业有限公司 (Sun Pharma) 宣布,干眼病治疗方案 Seciera™(0.09%环孢霉素A滴眼液)的第三阶段验证性临床实验已取得良好结果。